PEAK6 Group’s Esperion Therapeutics ESPR Stock Holding History

PEAK6 Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-10,000	Closed	-$223K	–	4563
2015 Q4	$223K	Sell	10,000 -5,000	-33%	-$126K	﹤0.01%	3351
2015 Q3	$354K	Buy	15,000 +13,500	+900%	+$847K	﹤0.01%	3214
2015 Q2	$123K	Sell	1,500 -28,100	-95%	-$2.75M	﹤0.01%	4125
2015 Q1	$2.74M	Buy	+29,600	New	+$1.91M	0.02%	1041

Other funds holding ESPR

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

PEAK6 Group's ESPR Position: Q4 2015 in Review

PEAK6 Group sold out of Esperion Therapeutics (ESPR) in Q4 2015, closing a stake of 2,615 shares — an estimated $66K sold.

PEAK6 Group first reported a position in ESPR in Q2 2015 and held it in 2 quarters. The position peaked at $62K in Q3 2015. 113 funds tracked by Wall St. Rank hold ESPR as of Q4 2015.

PEAK6 Group reported no remaining Esperion Therapeutics position as of Q4 2015 after selling out during the quarter.
PEAK6 Group sold 2,615 Esperion Therapeutics shares in Q4 2015, an estimated $66K.
PEAK6 Group first reported a position in Esperion Therapeutics in Q2 2015 and held it in 2 quarters.
PEAK6 Group's Esperion Therapeutics position peaked at $62K in Q3 2015.
113 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.